The EU’s Pharmaceutical Legislation Reform

Posted on

4 Apr


Dittmar & Indrenius > Insight > The EU’s Pharmaceutical Legislation Reform

The European Union’s imminent pharmaceutical legislation reform aims to modernise its regulatory framework, focusing on improving patient access to medicines, fostering innovation, and minimising environmental impact. This strategic overhaul, set against a backdrop of industry challenges and evolving IP rights, underscores the EU’s commitment to balancing innovation with accessibility and sustainability in healthcare.

The European Union (EU) is on the brink of enacting a major overhaul of its pharmaceutical legislation, aimed at modernising the regulatory framework to better meet the needs of patients and the pharmaceutical industry. The core objectives of this legislative reform are multifaceted, focusing on enhancing patient access to medicines, ensuring the security of the pharmaceutical supply chain, fostering an environment conducive to innovation, and minimising the environmental impact of pharmaceutical products. The 4-part reform package consists of a newly proposed Regulation, a Directive, a Communication on Pharmaceutical Reform, and a Council Recommendation on antimicrobial resistance. Both the Paediatric and Orphan Regulation will be incorporated into the new Regulation and Directive.

At the heart of these changes is a push towards making medicines more accessible to patients by addressing current disparities in drug availability. This involves not only ensuring that innovative treatments can reach the market more swiftly but also that existing medicines are readily available to all EU citizens, irrespective of where they live. The legislation is designed to mitigate the risk of drug shortages, a concern that has been underscored by recent global events which highlighted the fragility of supply chains.

To bolster innovation, the EU plans to streamline the regulatory process, significantly reducing the time required for the review and approval of new drugs. This includes reorganising the European Medicines Agency’s scientific committees to expedite the drug approval process, thereby making the EU a more attractive destination for pharmaceutical research and production.

Environmental concerns are also being addressed, with the legislation aiming to reduce the pharmaceutical industry’s environmental footprint. This includes tackling challenges such as antimicrobial resistance and the presence of pharmaceuticals in the environment, ensuring a holistic approach to health and sustainability.

The changes have also raised concerns in the industry. The proposal could notably impact R&D, particularly in terms of intellectual property (IP) exclusivity and innovation. It proposes significant changes to IP rights in Europe, introducing complex criteria for regaining lost IP protection. Innovators might secure greater protection for products meeting unmet medical needs or through a comprehensive European launch strategy. However, the legislation also presents challenges for pharmaceutical companies in fully safeguarding their IP rights, potentially leading to increased costs and a deceleration of R&D efforts within Europe.

The reform also introduces modifications to the regulatory data protection period, potentially altering the landscape for innovative pharmaceutical companies. These changes have sparked concerns among these companies, as they could impact the duration of market exclusivity, thus affecting the return on investment for new and innovative treatments. The apprehension lies in balancing the need for public access to affordable medicines with safeguarding the incentives for developing ground-breaking medical therapies.

The road to enacting these changes is anticipated to be long and complex, with the legislative process expected to extend until at least late 2025 or 2026. This timeline reflects the thorough consultation and scrutiny required for such a comprehensive overhaul of the pharmaceutical regulatory framework, as well as potential delays due to the European Parliament elections in 2024.

This reform represents a critical step towards addressing current challenges within the EU’s pharmaceutical sector, aiming to balance the goals of innovation, accessibility, and sustainability. As these legislative changes progress, it will be essential for all stakeholders, especially innovative pharmaceutical companies, to stay informed and prepared to adapt to the evolving regulatory landscape.

More by the same author

The European Parliament and the Council reach an agreement on European Health Data Space!

Towards a stronger European Health Union On March 15, 2024, the European Parliament and the Belgian Presidency of the Council reached a provisional political agreement on the European Health Data Space (EHDS) which is considered one of the central building blocks towards a stronger European Health Union. The upcoming EHDS aims to harness the full potential offered by the sharing, use, and re-use of health data, while ensuring full compliance with the data protection standards in the EU. This marks a significant milestone in the EU’s health data regulation.

Commission proposes extension of IVDR transition periods for legacy products

The European Commission has on 23 January 2024 announced a proposal for an extension to the transition period for the forthcoming In Vitro Diagnostic Medical Devices Regulation (IVDR). The aim is to ensure patient care by improving the availability of these essential healthcare products. In addition, the Commission also proposes measures to enable and accelerate a gradual roll out of EUDAMED, a database that will contain information about all medical devices and in vitro diagnostics (IVDs) placed on the EU market. The mandatory use of finalised parts of EUDAMED will support all key players in the implementation of the regulatory framework and enhance transparency for the public.

Examining Off-label Medicine Use in Paediatric Healthcare

Our life science experts Dr Juli Mansnérus, Charlotta Bonsdorff and Petro Vornanen seized the opportunity to contribute to the intricate field of medical law as they provided their expertise to the Office of the Ombudsman for Children in the form of an article regarding off-label medicine use in children.

Latest insights

Are Finnish Lawyers the Happiest in the World?

Article / 4 Apr 2024
Reading time 2 minutes

Implementing the Data Act without Clashing with the GDPR?

Article / 4 Apr 2024